Dear editor, The anti-tuberculosis drug concentrations in tuberculosis patients with and without diabetes mellitus were studied by AK Hemanth Kumar et al., and the results were published recently [1] . With diabetes mellitus being an established factor increasing the risk of treatment failure, relapse, and death in tuberculosis patients [2] , it is necessary to investigate the possible mechanisms behind the association.
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The authors' effort to address the issue by investigating the variability in plasma drug concentrations in diabetic and nondiabetic tuberculosis patients though appreciable has a number of shortcomings. Sixteen percent of the patients in the TB + DM group were labelled diabetic based on a single random blood glucose estimation on the study day, without proper elicitation of history for symptoms of hyperglycemia; this is in violation of the diagnostic criteria for diabetes mellitus [3] . In estimating the plasma drug concentrations, a multiple timepoint sample collection aimed at demonstrating the AUC would have been more informative and robust rather than a single time point sample collection [4] . Isoniazid metabolism and subsequently the plasma drug concentrations are known to be influenced by the acetylator status of the individual, but this key association has been neglected in the study [5] .
In the sample size estimation, selection of a higher true difference in the plasma drug concentrations could have led to a reduction in the sample size without affecting the results. The coefficient value for association between gender and pyrazinamide concentrations (−2.363) has not been specified for the gender type. The correlation coefficient at r = −0.09 for isoniazid and r = −0.092 for pyrazinamide demonstrate a very weak correlation despite the statistical significance. Moreover, the plasma drug concentrations for both isoniazid and pyrazinamide show only a relative variability, and the drug concentrations are within the normal therapeutic range for the respective drugs. This makes for a very weak or rather non-existent clinical implication for the results.
In spite of failing to add new information on the mechanisms behind the association of diabetes mellitus and poorer outcome in tuberculosis patients, the study brings to light the possibility of exploring the pharmacokinetics of isoniazid and pyrazinamide in the setting of elevated blood glucose levels.
